Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
01:43:14 EDT Sat 16 May 2026
Enter Symbol
or Name
USA
CA



Forgot password?
Trouble logging in?
Login ID:
Password:
Save

Q:INSM - INSMED INC - https://www.insmed.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
INSM - Q5.9109.14·112.600.2109.14-6.48-5.63,688.2404,21030,195114.30  114.51  108.22212.75  64.8519:59:05May 0715 min RT 2¢

Recent Trades - Last 10 of 30195
Time ETExPriceChangeVolume
19:59:05Q109.94-5.6820
19:56:05Q108.3318-7.288250
19:41:08Q109.20-6.4220
19:24:05Q109.8948-5.72523
19:08:41Q109.20-6.4213
18:58:28Q109.20-6.4230
18:50:23Q109.29-6.333
18:50:23Q109.20-6.4297
18:39:48Q109.00-6.62100
18:36:00Q109.50-6.12100

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-05-07 07:00U:INSMNews ReleaseInsmed Reports First-Quarter 2026 Financial Results and Provides Business Update
2026-05-06 16:30U:INSMNews ReleaseInsmed and Ty Pennington Team Up to Drive Awareness and Proper Diagnosis of Bronchiectasis
2026-05-04 07:00U:INSMNews ReleaseInsmed to Present Data Across Its Respiratory Portfolio, Including Late-Breaking ARIKAYCE(TM) Results from Phase 3b ENCORE Study, at the American Thoracic Society International Conference 2026
2026-04-30 07:00U:INSMNews ReleaseInsmed to Present at May 2026 Investor Conferences
2026-04-23 07:00U:INSMNews ReleaseInsmed to Host First-Quarter 2026 Financial Results Conference Call on Thursday, May 7, 2026
2026-04-07 16:01U:INSMNews ReleaseInsmed Provides Clinical Update on Phase 2b CEDAR Study
2026-03-23 07:00U:INSMNews ReleaseInsmed Announces Positive Topline Results from Phase 3b ENCORE Study of ARIKAYCE(TM) (Amikacin Liposome Inhalation Suspension) in Patients with MAC Lung Disease
2026-03-05 07:00U:INSMNews ReleaseInsmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2026-02-19 07:00U:INSMNews ReleaseInsmed Reports Fourth-Quarter and Full-Year 2025 Financial Results and Provides Business Update
2026-02-13 07:00U:INSMNews ReleaseInsmed To Present at March 2026 Investor Conferences
2026-02-05 07:00U:INSMNews ReleaseInsmed to Host Fourth-Quarter and Full-Year 2025 Financial Results Conference Call on Thursday, February 19, 2026
2026-01-28 07:00U:INSMNews ReleaseInsmed to Present Multiple Abstracts on Treprostinil Palmitil Inhalation Powder (TPIP) at Pulmonary Vascular Research Institute (PVRI) 2026 Congress
2026-01-09 07:00U:INSMNews ReleaseInsmed Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference
2026-01-02 07:00U:INSMNews ReleaseInsmed To Present at the 44th Annual J.P. Morgan Healthcare Conference
2025-12-17 16:01U:INSMNews ReleaseInsmed Provides Clinical and Business Update
2025-12-04 07:00U:INSMNews ReleaseInsmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2025-11-18 11:00U:INSMNews ReleaseEuropean Commission Approves BRINSUPRI(TM) (brensocatib) as the First and Only Treatment Approved for Non-Cystic Fibrosis Bronchiectasis in the European Union
2025-11-13 07:00U:INSMNews ReleaseInsmed Strengthens Communities Worldwide During Fourth Annual Global Day of Good
2025-11-05 07:00U:INSMNews ReleaseInsmed To Present at November and December 2025 Investor Conferences
2025-10-30 07:00U:INSMNews ReleaseInsmed Reports Third-Quarter 2025 Financial Results and Provides Business Update